DWTX — Dogwood Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1818844 ·
Last close
$1.08
Market Cap
$41.29M
52W High
$7.04
52W Low
$0.90
ADV30
97,623
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 100,000 | 11,896 | -4,917,300 | -4,882,942 | 75,608,219 | 4,948,266 | 11,475,000 |
| Jun 2026 | 0 | — | -4,872,628 | -11,529,609 | 80,495,480 | 9,610,033 | 12,129,372 |
| Mar 2026 | 0 | — | -5,076,366 | -4,986,614 | 95,207,871 | 13,227,839 | 14,584,519 |
| Dec 2025 | 0 | — | -3,806,279 | -3,780,449 | 90,171,237 | 6,524,744 | 15,274,370 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,108,253
Investing CF
—
Financing CF
$11,323,909
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.95
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-124,592,539
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-29,564,398
Pretax Income TTM
$-38,490,384
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -27,968,445 | -34,257,370 | 90,171,237 | 15,274,370 | 74,896,867 | -15,618,651 |
| Dec 2024 | 0 | -12,227,248 | -12,349,724 | 94,308,246 | 30,027,223 | 64,281,023 | -8,790,805 |
| Dec 2023 | 0 | -5,446,919 | -5,296,015 | 4,165,442 | 358,548 | 3,806,894 | -4,870,489 |
| Dec 2022 | 0 | -12,315,309 | -12,247,834 | 8,369,756 | 1,043,262 | 7,326,494 | -11,467,797 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-36,041,288
OpCashFlow TTM
—
Assets (Latest)
$80,495,480
Forward EPS
$-6.37
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TLPH | TALPHERA, INC. | $41.61M | $0.80 | — |
| PLRX | PLIANT THERAPEUTICS, INC. | $40.93M | $0.66 | — |
| ALDX | Aldeyra Therapeutics, Inc. | $41.88M | $0.69 | — |
| ELTX | Elicio Therapeutics, Inc. | $40.48M | $1.43 | — |
| ATNM | Actinium Pharmaceuticals, Inc. | $42.45M | $1.35 | — |
News headlines (Yahoo Finance, 1h cache)
Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
2026-10-19 12:30 · Yahoo
Dogwood to Participate in the 2026 Maxim Growth Summit
2026-10-06 12:45 · Yahoo
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
2026-09-14 12:45 · Yahoo
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
2026-09-01 22:01 · Yahoo
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
2026-08-17 12:30 · Yahoo
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
2026-08-13 12:30 · Yahoo
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
2026-07-20 12:30 · Yahoo
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
2026-06-30 12:45 · Yahoo
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
2026-04-15 13:00 · Yahoo
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
2026-04-23 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.